<DOC>
	<DOC>NCT01353248</DOC>
	<brief_summary>The purpose of this phase 2 study is to determine whether 30 mg or 90 mg of GS-5885 when given with GS-9451, Tegobuvir and Ribavirin (RBV) for 12 or 24 weeks is effective, safe and tolerable in the treatment of Chronic Genotype 1 HCV Infection.</brief_summary>
	<brief_title>GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Adult subjects 18 to 70 years of age Chronic HCV infection for at least 6 months prior to Baseline (Day 1) Liver biopsy results (performed no more than 2 years prior to Screening) indicating the absence of cirrhosis Monoinfection with HCV genotype 1a or 1b HCV treatmentnaïve Body mass index (BMI) between 18 and 36 kg/m2 Creatinine clearance ≥ 50 mL/min Subject agrees to use highly effective contraception methods if female of childbearing potential or sexually active male. Screening laboratory values within defined thresholds Autoimmune disease Decompensated liver disease or cirrhosis Poorly controlled diabetes mellitus Severe psychiatric illness Severe chronic obstructive pulmonary disease (COPD) Serological evidence of coinfection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or another HCV genotype Suspicion of hepatocellular carcinoma or other malignancy (with exception of certain skin cancers) History of hemoglobinopathy Known retinal disease Subjects who are immunosuppressed Subjects with known, current use of amphetamines, cocaine, opiates (i.e., morphine, heroin), methadone, or ongoing alcohol abuse Subjects must have no history of clinically significant cardiac disease, including a family history of Long QT syndrome, and no relevant electrocardiogram (ECG) abnormalities at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>GS-5885</keyword>
	<keyword>GS-9451</keyword>
	<keyword>Tegobuvir</keyword>
</DOC>